Insulin resistance and inflammation markers in myocardial infarction

Olga Gruzdeva, Evgenya Uchasova, Yulia Dyleva, Ekaterina Belik, Ekaterina Shurygina, Olga Barbarash, Olga Gruzdeva, Evgenya Uchasova, Yulia Dyleva, Ekaterina Belik, Ekaterina Shurygina, Olga Barbarash

Abstract

Background: Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus, and is regarded as an important mechanism in disease pathogenesis. One of the key pathogenetic mechanisms of IR progression is impaired free fatty acid (FFA) metabolism. Plasminogen-activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive protein (CRP), also play a role.

Purpose: To assess the changing levels of the metabolic proinflammation IR markers IL-6, CRP and PAI-1 and their association with the presence or absence of type 2 diabetes mellitus in myocardial infarction (MI) patients during their hospital stay.

Methods: THE PATIENTS WERE DIVIDED INTO TWO GROUPS: group 1 included 95 nondiabetic MI patients, and group 2 enrolled 40 diabetic MI patients. The control group consisted of 30 sex-and age-matched volunteers. Serum IL-6 and CRP levels as well as FFA, glucose, C-peptide, insulin, and plasma PAI-1 concentrations were measured at days 1 and 12 from MI onset.

Results: At day 1, there was an increase in glucose concentrations, which remained high in both groups by day 12 but was much higher in the diabetic patients. Basal insulin and C-peptide levels did not differ significantly from those in the control group. The quantitative insulin sensitivity-check index in both groups was significantly different from that in controls. FFA concentrations at day 1 in both diabetic and nondiabetic patients increased; by day 12, they had decreased but were still higher than the controls. CRP and IL-6 levels at day 1 were higher in all the patients, but diabetic patients had the highest levels; by day 12, the levels were lower but still 2.4-fold (IL-6) and 12.5-fold (CRP) higher than those in the control group.

Conclusion: This study showed that MI is accompanied both by activated inflammatory response and IR. Strong correlations between IL-6 and FFA concentrations demonstrate that nonspecific inflammation factors are involved in IR development in MI patients. Consequently, these inflammatory cytokines might cause the development of IR.

Keywords: inflammation; insulin resistance; myocardial infarction; type 2 diabetes mellitus.

Figures

Figure 1
Figure 1
Correlation between C-reactive protein (CRP) levels and free fatty acids (FFA).
Figure 2
Figure 2
Correlation between basal levels of glucose and interleukin (IL)-6.
Figure 3
Figure 3
Correlation between C-reactive protein (CRP) levels and postprandial levels of glucose.
Figure 4
Figure 4
Correlation between plasminogen-activator inhibitor (PaI)-1 and interleukin (IL)-6.
Figure 5
Figure 5
Correlation between interleukin (IL)-6 levels and creatine kinase (CK) MB activity.
Figure 6
Figure 6
Correlation between C-reactive protein (CRP) levels and interleukin (IL)-6.

References

    1. Pickup J. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–823.
    1. Yu Q, Gao F, Ma XL. Insulin says NO to cardiovascular disease. Cardiovasc Res. 2011;89:516–524.
    1. Fernández JM, Rilcart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278–301.
    1. Smit JW, Romijn JA. Acute insulin resistance in myocardial ischemia: causes and consequences. Semin Cardiothorac Vasc Anesth. 2006;10:215–219.
    1. Antoinette M, Steffen L, Jacobs D, et al. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care. 2005;28:1763–1768.
    1. Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther. 2002;303:1007–1013.
    1. Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86:1154–1159.
    1. Geiger PC, Hancock C, Wright DC, Han DH, Holloszy JO. IL-6 increases muscle insulin sensitivity only at superphysiological levels. Am J Physiol Endocrinol Metab. 2007;292:1842–1846.
    1. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31–47.
    1. Collet JP, Montalescot G, Vicaut E, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003;108:391–394.
    1. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26:2200–2207.
    1. Juhan-Vague I, Morange PE, Frere C, et al. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin/insulin levels in men from Europe: the HIFMECH study. J Thromb Haemost. 2003;1:2322–2329.
    1. Kryzhanovsky VA. Diagnosis and treatment of myocardial infarction. K.: Phoenix; 2001.
    1. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–2410.
    1. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007;47:142–156.
    1. Cefalu WT. Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 2001;226:13–26.
    1. Papanicolaou DA, Vgontzas AN. Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab. 2000;85:1331–1333.
    1. Nieto-Vazquez I, Fernández-Veledo S, de Alvaro C, Lorenzo M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes. 2008;57:3211–3221.
    1. Opie LH, Knuuti J. The adrenergic-fatty acid load in heat failure. J Am Coll Cardiol. 2009;54:1637–1646.
    1. Gwechenberger M, Mendoza LH, Youker KA, et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions circulation. Circulation. 1999;99:546–551.
    1. Pravenec M, Kajiya T, Zídek V, et al. Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension. 2011;57:731–737.
    1. D’Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia. 2007;50:840–849.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner